This K02 application proposes support essential for my career development as a newly independent researcher in brain imaging of addiction and tobacco smoking. Through a K01 funded by NIDA, I attained considerable expertise in brain imaging of tobacco smokers, with a focus on sex differences. I have demonstrated considerable research productivity as evidenced by my increasing number of peer reviewed publications and current grant funding including being principal investigator on two R01s. This K02 award is vital for providing focused research time and for facilitating my maturation into a fully-independent investigator. My current career goal is to use SPECT and PET imaging to examine brain receptor changes during acute and prolonged abstinence from tobacco smoking and to determine biomarkers that may modulate these receptor changes and thus impact tobacco smoking cessation efforts. Included in the proposal is a rigorous 5-year career development training plan that fills important gaps and complements my current expertise in SPECT/PET neuroreceptor imaging. Specifically, I plan to broaden my knowledge in the three areas of genetics, cognition and fMRI, so that I can integrate them in my research on tobacco smoking and addiction in order to have a greater impact on future treatment. Intensive training is provided by an integrated curriculum of intramural coursework, extramural short courses, three individualized preceptorships, interactive symposia, and research-related organizational meetings. A primary NIDA funded research study (R01) is included that examines genetic influences on nicotinic acetylcholine receptor availability in habitual tobacco smokers and nonsmokers. We have previously demonstrated using [123I]5-IA-85380 and SPECT brain imaging that beta2-subunit containing nicotinic acetylcholine receptors (beta2-nAChRs) are higher (26-36%) in the striatum, and throughout the cerebral cortex and cerebellum in tobacco smokers versus nonsmokers and that it takes up to 6-12 of abstinence for these receptors to return to control levels. The findings from the latter study were heterogeneous, with some subjects showing decreases of up to 17% over abstinence and others showing minimal change, e.g., 4%. The goal of the current study is to determine whether this individual variability in beta-nAChR availability during acute and prolonged abstinence is genetically mediated. In the present proposal, we aim to validate this hypothesis through the following specific aims: 1) to determine if beta2-nAChR availability is genetically determined in European-American (EA) never smokers, 2) to determine if the adaptive increase in beta2-nAChR availability in EA smokers is genetically determined and 3) to determine if the change in beta2-nAChR availability over the first 6-8 weeks of abstinence in EA smokers from Aim 2 is genetically determined. The focus is on 2 genes that have been associated with nicotine dependence, the CHRNA4 and ANKK1. The findings from these studies may provide definitive genetic and neurochemical evidence that will allow in future studies for smokers to be stratified and tested for responses to various smoking cessation treatments.

Public Health Relevance

Smoking is the leading known cause of preventable death, yet 25% of the American population continues to smoke. The nicotinic acetylcholine receptor (nAChR) is a critical neurochemical substrate involved in the addiction to cigarette smoking. These studies will define the genes and brain chemicals that may contribute to individual differences in tobacco smoking and will help to design treatment studies that will ultimately help tailor smoking cessation treatments.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Scientist Development Award - Research (K02)
Project #
Application #
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Gordon, Harold
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Schools of Medicine
New Haven
United States
Zip Code
Hillmer, A T; Esterlis, I; Gallezot, J D et al. (2016) Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. Neuroimage 141:71-80
Hillmer, Ansel T; Kloczynski, Tracy; Sandiego, Christine M et al. (2016) Nicotine and Nicotine Abstinence Do Not Interfere with GABAA Receptor Neuroadaptations During Alcohol Abstinence. Alcohol Clin Exp Res 40:698-705
Yoder, Karmen K; Territo, Paul R; Hutchins, Gary D et al. (2015) Comparison of standardized uptake values with volume of distribution for quantitation of [(11)C]PBR28 brain uptake. Nucl Med Biol 42:305-8
Weinberger, Andrea H; Smith, Philip H; Allen, Sharon S et al. (2015) Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. Nicotine Tob Res 17:407-21
Bois, Frederic; Gallezot, Jean-Dominique; Zheng, Ming-Qiang et al. (2015) Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. Nucl Med Biol 42:570-7
Sandiego, Christine M; Gallezot, Jean-Dominique; Lim, Keunpoong et al. (2015) Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET. J Cereb Blood Flow Metab 35:623-9
Cosgrove, Kelly P; Veldhuizen, Maria G; Sandiego, Christine M et al. (2015) Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Synapse 69:195-202
Verplaetse, Terril L; Weinberger, Andrea H; Smith, Philip H et al. (2015) Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. Nicotine Tob Res 17:486-95
Cosgrove, Kelly P; Esterlis, Irina; Sandiego, Christine et al. (2015) Imaging Tobacco Smoking with PET and SPECT. Curr Top Behav Neurosci 24:1-17
Gaiser, Edward C; Matuskey, David; Perkins, Evgenia et al. (2015) A case series on the heightened autonomic response due to guanfacine and amphetamine interaction. J Clin Psychopharmacol 35:197-9

Showing the most recent 10 out of 22 publications